Society for Translational Oncology navigateright Episode
Ibiayi Dagogo-Jack, MD
Massachusetts General Hospital
To date, analysis of biopsies from progressive lesions has been the primary method of characterizing resistance to ALK TKIs. These analyses have identified acquired ALK resistance mutations in more than half of patients relapsing on a second-generation TKI. This lecture reviews the molecular basis of acquired resistance to next-generation ALK TKIs, discusses the impact of heterogeneity on response to ALK therapies, demonstrates that plasma genotyping reliably detects ALK resistance mutations, and presents emerging data supporting the potential for liquid biopsies to refine current understanding of determinants of ALK TKI response.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.